Calcitonin in treatment of shoulder capsulitis

Calcitonin effects on shoulder Adhesive capsulitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013080414271N1

Enrollment

Registered

2013-08-25

Start date

2013-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder adhesive capsulitis. Adhesive capsulitis of shoulder

Interventions

Intervention 1: For intervention group: Calcitonin 200 units/mg nasal spray made by Sina Darou Corporation will be administered for six weeks. Intervention 2: For control group: Placebo nasal spray wi

Treatment - Drugs

Placebo

For intervention group: Calcitonin 200 units/mg nasal spray made by Sina Darou Corporation will be administered for six weeks.

For control group: Placebo nasal spray with the same shape and size of the Calcitonin nasal spray made by Sina Darou one puff daily for sex weeks will be administered.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: (To have shoulder adhesive capsulitis; not to have history of surgery or any prior trauma to the shoulder; not to have a systemic disease like diabetes or hypo or hyperthyroidism; not to receive any kind of systemic corticosteroid) Exclusion criteria: (Occurrence of intolerable adverse effects)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain severity. Timepoint: Before the initiation of the treatment and 3, 6 and 12 weeks after the initiation of the treatment. Method of measurement: Using Visual Analog Scale.;Shoulder range of motion. Timepoint: Before the initiation of the treatment and 3, 6 and 12 weeks after the initiation of the treatment. Method of measurement: Using physical examination.;DASH score. Timepoint: Before the initiation of the treatment and 3, 6 and 12 weeks after the initiation of the treatment. Method of measurement: Using DASH questionnaire.;SPADI score. Timepoint: Before the initiation of the treatment and 3, 6 and 12 weeks after the initiation of the treatment. Method of measurement: Using SPADI questionnaire.;HAQ score. Timepoint: Before the initiation of the treatment and 3, 6 and 12 weeks after the initiation of the treatment. Method of measurement: Using HAQ questionnaire.	—

Measure

Time frame

Pain severity. Timepoint: Before the initiation of the treatment and 3, 6 and 12 weeks after the initiation of the treatment. Method of measurement: Using Visual Analog Scale.;Shoulder range of motion. Timepoint: Before the initiation of the treatment and 3, 6 and 12 weeks after the initiation of the treatment. Method of measurement: Using physical examination.;DASH score. Timepoint: Before the initiation of the treatment and 3, 6 and 12 weeks after the initiation of the treatment. Method of measurement: Using DASH questionnaire.;SPADI score. Timepoint: Before the initiation of the treatment and 3, 6 and 12 weeks after the initiation of the treatment. Method of measurement: Using SPADI questionnaire.;HAQ score. Timepoint: Before the initiation of the treatment and 3, 6 and 12 weeks after the initiation of the treatment. Method of measurement: Using HAQ questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahmoud Barzgar

Tabriz University of Medical Sciences

Mahmud.barzgar@yahoo.com+98 41 1335 7310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026